Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Parallel-group Study of the Safety and Tolerability of REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate.

Next Previous
Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Parallel-group Study of the Safety and Tolerability of REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarilumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions

Most Recent Events

  • 26 May 2020 Results of Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab from four phase I-III studies (NCT01011959, NCT01061736, NCT01709578, NCT01768572 ) published in the Clinical Pharmacokinetics
  • 16 Nov 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01011959).
  • 13 Nov 2009 Actual start date (December 2008), official title, actual patient number (60), location (USA), primary outcome, lead investigator (Radin A) and sanofi-aventis added as trial sponsor as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top